Katz, Nov 4, A021501 summary slides
Advances in Pancreatic SBRT
PDF) Alliance for clinical trials in oncology (ALLIANCE) trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Two studies pave the way for preoperative therapy in pancreatic cancer patients | The Bulletin
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era
management of pancreatic cancer.pptx
fig2_schema | The Bulletin
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas | BMC Cancer
Katz, Nov 4, A021501 summary slides
Katz, Nov 4, A021501 summary slides
Preoperative combination chemotherapy improved survival in patients with pancreatic cancer | MD Anderson Cancer Center
The Landmark Series: Preoperative Therapy for Pancreatic Cancer | SpringerLink
Peter Hosein, MD on X: "Long awaited results of the Alliance A021501 for borderline resectable PDAC presented by @mkatzmd @ASCO #GI21. Over to you #Radonctwitter 🧐 https://t.co/rFlVNpSoBW" / X
The Landmark Series: Preoperative Therapy for Pancreatic Cancer | SpringerLink
POST SFRO 2022.pptx
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial - The Lancet ...
Emergence of SBRT in borderline resectable pancreatic cancer: Is it the way forward?
Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer - YouTube
Alliance for Clinical Trials in Oncology - Take a look at A021501 – a trial led by @MKatzMD @MDAndersonNews that looks at how well combination chemotherapy and high-dose radiation therapy before surgery
Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results | The Bulletin
Neoadjuvant mFOLFIRINOX Established as Reference Standard in Borderline Resectable PDAC
